Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_2
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Not yet recruiting1
Active, not recruiting1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting125%
active_not_recruiting125%
unknown125%
recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

NCT07229625
active_not_recruitingphase_2

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

NCT04392505
not_yet_recruitingphase_1

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

NCT06111326
unknownnot_applicable

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

NCT04443322

Clinical Trials (4)

Showing 4 of 4 trials
NCT07229625Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Recruiting
NCT04392505Phase 2

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Active Not Recruiting
NCT06111326Phase 1

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Not Yet Recruiting
NCT04443322Not Applicable

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4